Annual CFO
-$23.79 M
-$12.05 M-102.77%
December 31, 2024
Summary
- As of March 13, 2025, APVO annual cash flow from operations is -$23.79 million, with the most recent change of -$12.05 million (-102.77%) on December 31, 2024.
- During the last 3 years, APVO annual CFO has fallen by -$2.11 million (-9.71%).
- APVO annual CFO is now -102.77% below its all-time high of -$11.73 million, reached on December 31, 2023.
Performance
APVO Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFO
-$5.76 M
-$537.00 K-10.28%
December 31, 2024
Summary
- As of March 13, 2025, APVO quarterly cash flow from operations is -$5.76 million, with the most recent change of -$537.00 thousand (-10.28%) on December 31, 2024.
- Over the past year, APVO quarterly CFO has dropped by -$506.00 thousand (-9.63%).
- APVO quarterly CFO is now -226.13% below its all-time high of $4.57 million, reached on March 31, 2023.
Performance
APVO Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFO
-$23.79 M
-$506.00 K-2.17%
December 31, 2024
Summary
- As of March 13, 2025, APVO TTM cash flow from operations is -$23.79 million, with the most recent change of -$506.00 thousand (-2.17%) on December 31, 2024.
- Over the past year, APVO TTM CFO has dropped by -$12.05 million (-102.77%).
- APVO TTM CFO is now -109.76% below its all-time high of -$11.34 million, reached on March 31, 2023.
Performance
APVO TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Operations Formula
CFO = Net Income + Non Cash Expenses + Changes In Working Capital
APVO Cash From Operations Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -102.8% | -9.6% | -102.8% |
| 3 y3 years | -9.7% | -9.6% | -102.8% |
| 5 y5 years | +43.9% | -9.6% | -102.8% |
APVO Cash From Operations Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -102.8% | at low | -226.1% | +16.5% | -109.8% | +2.1% |
| 5 y | 5-year | -102.8% | +43.9% | -226.1% | +48.5% | -109.8% | +43.9% |
| alltime | all time | -102.8% | +53.8% | -226.1% | +66.1% | -109.8% | +60.1% |
Aptevo Therapeutics Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2024 | -$23.79 M(+102.8%) | -$5.76 M(+10.3%) | -$23.79 M(+2.2%) |
| Sep 2024 | - | -$5.22 M(-15.1%) | -$23.28 M(-4.2%) |
| Jun 2024 | - | -$6.15 M(-7.5%) | -$24.30 M(+5.9%) |
| Mar 2024 | - | -$6.65 M(+26.6%) | -$22.95 M(+95.6%) |
| Dec 2023 | -$11.73 M(-44.2%) | -$5.25 M(-15.8%) | -$11.73 M(-5.5%) |
| Sep 2023 | - | -$6.24 M(+29.9%) | -$12.42 M(-5.0%) |
| Jun 2023 | - | -$4.80 M(-205.2%) | -$13.07 M(+15.3%) |
| Mar 2023 | - | $4.57 M(-176.9%) | -$11.34 M(-46.1%) |
| Dec 2022 | -$21.02 M(-3.0%) | -$5.94 M(-13.9%) | -$21.02 M(+10.9%) |
| Sep 2022 | - | -$6.90 M(+124.6%) | -$18.96 M(+9.6%) |
| Jun 2022 | - | -$3.07 M(-40.0%) | -$17.31 M(-10.3%) |
| Mar 2022 | - | -$5.12 M(+31.9%) | -$19.29 M(-11.0%) |
| Dec 2021 | -$21.68 M(-26.1%) | -$3.88 M(-26.0%) | -$21.68 M(-9.4%) |
| Sep 2021 | - | -$5.24 M(+3.7%) | -$23.92 M(-8.2%) |
| Jun 2021 | - | -$5.05 M(-32.7%) | -$26.07 M(+1.6%) |
| Mar 2021 | - | -$7.50 M(+22.6%) | -$25.65 M(-12.5%) |
| Dec 2020 | -$29.32 M(-30.8%) | -$6.12 M(-17.1%) | -$29.32 M(+3.6%) |
| Sep 2020 | - | -$7.39 M(+59.4%) | -$28.30 M(-0.6%) |
| Jun 2020 | - | -$4.63 M(-58.5%) | -$28.46 M(-28.3%) |
| Mar 2020 | - | -$11.18 M(+119.1%) | -$39.71 M(-6.3%) |
| Dec 2019 | -$42.38 M | -$5.10 M(-32.4%) | -$42.38 M(-4.9%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2019 | - | -$7.55 M(-52.5%) | -$44.58 M(-7.5%) |
| Jun 2019 | - | -$15.89 M(+14.8%) | -$48.17 M(-0.2%) |
| Mar 2019 | - | -$13.84 M(+89.9%) | -$48.29 M(-6.1%) |
| Dec 2018 | -$51.42 M(+23.7%) | -$7.29 M(-34.6%) | -$51.42 M(-13.7%) |
| Sep 2018 | - | -$11.15 M(-30.4%) | -$59.55 M(+19.1%) |
| Jun 2018 | - | -$16.01 M(-5.7%) | -$50.02 M(+7.5%) |
| Mar 2018 | - | -$16.98 M(+10.1%) | -$46.52 M(+11.9%) |
| Dec 2017 | -$41.57 M(+12.8%) | -$15.42 M(+854.3%) | -$41.57 M(+26.7%) |
| Sep 2017 | - | -$1.62 M(-87.1%) | -$32.82 M(+4.7%) |
| Jun 2017 | - | -$12.51 M(+4.0%) | -$31.34 M(-9.9%) |
| Mar 2017 | - | -$12.03 M(+80.5%) | -$34.78 M(-5.7%) |
| Dec 2016 | -$36.86 M(-24.4%) | -$6.67 M(+4873.9%) | -$36.86 M(-2.7%) |
| Sep 2016 | - | -$134.00 K(-99.2%) | -$37.88 M(-19.6%) |
| Jun 2016 | - | -$15.95 M(+13.0%) | -$47.10 M(+0.3%) |
| Mar 2016 | - | -$14.11 M(+83.7%) | -$46.95 M(-3.7%) |
| Dec 2015 | -$48.76 M(+3.7%) | -$7.68 M(-17.9%) | -$48.76 M(+18.7%) |
| Sep 2015 | - | -$9.36 M(-40.8%) | -$41.08 M(+29.5%) |
| Jun 2015 | - | -$15.80 M(-0.7%) | -$31.72 M(+99.3%) |
| Mar 2015 | - | -$15.92 M | -$15.92 M |
| Dec 2014 | -$47.01 M(-8.5%) | - | - |
| Dec 2013 | -$51.39 M | - | - |
FAQ
- What is Aptevo Therapeutics annual cash flow from operations?
- What is the all time high annual CFO for Aptevo Therapeutics?
- What is Aptevo Therapeutics annual CFO year-on-year change?
- What is Aptevo Therapeutics quarterly cash flow from operations?
- What is the all time high quarterly CFO for Aptevo Therapeutics?
- What is Aptevo Therapeutics quarterly CFO year-on-year change?
- What is Aptevo Therapeutics TTM cash flow from operations?
- What is the all time high TTM CFO for Aptevo Therapeutics?
- What is Aptevo Therapeutics TTM CFO year-on-year change?
What is Aptevo Therapeutics annual cash flow from operations?
The current annual CFO of APVO is -$23.79 M
What is the all time high annual CFO for Aptevo Therapeutics?
Aptevo Therapeutics all-time high annual cash flow from operations is -$11.73 M
What is Aptevo Therapeutics annual CFO year-on-year change?
Over the past year, APVO annual cash flow from operations has changed by -$12.05 M (-102.77%)
What is Aptevo Therapeutics quarterly cash flow from operations?
The current quarterly CFO of APVO is -$5.76 M
What is the all time high quarterly CFO for Aptevo Therapeutics?
Aptevo Therapeutics all-time high quarterly cash flow from operations is $4.57 M
What is Aptevo Therapeutics quarterly CFO year-on-year change?
Over the past year, APVO quarterly cash flow from operations has changed by -$506.00 K (-9.63%)
What is Aptevo Therapeutics TTM cash flow from operations?
The current TTM CFO of APVO is -$23.79 M
What is the all time high TTM CFO for Aptevo Therapeutics?
Aptevo Therapeutics all-time high TTM cash flow from operations is -$11.34 M
What is Aptevo Therapeutics TTM CFO year-on-year change?
Over the past year, APVO TTM cash flow from operations has changed by -$12.05 M (-102.77%)